Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific Corp Receives FDA 510(k) Clearance for Rhythmia Mapping System


Wednesday, 24 Jul 2013 06:14pm EDT 

Boston Scientific Corp announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rhythmia Mapping System, 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures to diagnose or treat a variety of conditions in which the heart beats abnormally. Cardiac mapping has become a standard tool for the diagnosis and treatment of arrhythmias. Current mapping systems require a manual, labor intensive process to create maps, making tradeoffs between accuracy and speed. Current systems also offer limited indication of therapy success. The Rhythmia Mapping System is designed to intelligently automate map creation, increasing the speed and improving the density of mapping compared to existing systems. The system also features vMap, a validation map, which is designed to enable electrophysiologists, for the first time, to rapidly confirm the endpoints of the ablation treatment. Boston Scientific is offering the Rhythmia Mapping System with the Company's 64-electrode IntellaMap Orion High Resolution Mapping Catheter, which has also received FDA 510(k) clearance. 

Company Quote

12.94
-0.01 -0.08%
21 Nov 2014